Genomics Startup in FDA Feud Still Has No GC

, The Recorder


PALO ALTO — On paper, the top legal job at 23andMe might look like one of the hottest tickets in town. The high-profile Mountain View–based company, backed by Google and run by Anne Wojcicki, has pioneered the potentially paradigm-shifting personal genomics model. The job arguably just got more interesting when the Food and Drug Administration strong-armed the company into ceasing its interpretation of genetic test results. 23andMe now faces several class actions related to its regulatory missteps.

This article has been archived, and is no longer available on this website.

View this content exclusively through LexisAdvance® Here

Not a LexisAdvance® Subscriber?

Subscribe Now

LexisAdvance® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisAdvance® customers will be able to access and use ALM's content by subscribing to the LexisAdvance® services via® and Nexis®. This includes content from The National Law Journal®, The American Lawyer®, Legaltech News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisAdvance® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202641073928

Thank you!

This article's comments will be reviewed.